Source: Genetic engineering production, E. coli expression
一、Product Introduction
Liraglutide is an analogue of human hyperinsulin-like peptide-1 (GLP-1) that can stimulate insulin secretion in a glucose concentration dependent manner, while reducing excessive glucagon secretion in a glucose concentration dependent manner, delaying gastric emptying, and reducing food intake through central appetite control; Lilalutide can also enhance the sensitivity of peripheral tissues to insulin, thereby reducing postprandial blood sugar and weight. Therefore, in clinical practice, lilalutide can be used alone or in combination with other oral hypoglycemic drugs to control weight or treat type 2 diabetes.
Structural formula:
二、Product features
| Item | Specification | Results | |||
| Peptide mapping | Mapping file is same to reference | Compliance | |||
| Test | Related protein | Hydrophilic impurity | ≤2.5% | 0.4% | |
| Hydrophobic impurity | ≤0.5% | 0.2% | |||
| Total impurities | ≤5.2% | 1.4% | |||
| HWMP | ≤0.7% | 0.04% | |||
| Bioburden | Less than 100cfu/g | Compliance | |||
| Bacterial endotoxin | Less than 10 EU/mg | Compliance | |||
| HCP | Less than 100ng/mg | Compliance | |||
| Residual solvent | ethnol | ≤5000ppm | 54ppm | ||
| ACN | ≤410ppm | 55ppm | |||
| Triethylamine | ≤5000ppm | Not detect | |||
三、Product advantages
1、Production form: Biological fermentation semi synthesis, high solubility, low protein aggregation, and high in vitro activity
2、Factory capacity: 1000L fermentation tank with an annual output of 60kg
3、Technical support: stability research and support for DMF application
四、Related products
Liraglutide related side chains; Smegglutide; Tilposide.